

=&gt; d ibib abs hitrn 122 1-2

L22 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:410373 HCAPLUS

DOCUMENT NUMBER: 137:137428

TITLE: Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives: II. The combination of amino acid residues in the dipeptidic moiety and its effect on the anti-Helicobacter pylori activity

AUTHOR(S): Hasuoka, Atsushi; Nishikimi, Yuji; Nakayama, Yutaka; Kamiyama, Keiji; Nakao, Masafumi; Miyagawa, Ken-Ichiro; Nishimura, Osamu; Fujino, Masahiko

CORPORATE SOURCE: Medicinal Chemistry Research Laboratories I, Pharmaceutical Research Division, Takeda Chemical Industries, Ltd., Osaka, 532-8686, Japan

SOURCE: Journal of Antibiotics (2002), 55(5), 499-507

CODEN: JANTAJ; ISSN: 0021-8820

PUBLISHER: Japan Antibiotics Research Association

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The novel natural antibiotics pyloricidin A, B and C, consisting of a common (2S,3R,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexanoyl-.beta.-D-phenylalanine moiety and a terminal peptidic moiety (pyloricidin A: L-valine-L-valine-L-leucine; pyloricidin B: L-valine-L-leucine; pyloricidin C: L-leucine), exhibit potent and highly selective anti-Helicobacter pylori activity. In order to develop more potent compds. and to investigate structure activity relationships for the peptidic moiety with regard to the combination of amino acids, a series of derivs. with various dipeptidic moieties were prepd. and evaluated for their anti-H. pylori activity. The combination of the two amino acids in the moiety was found to have a significant effect on the activity; the compd. with Nva-Abu showed excellent anti-H. pylori activity with an MIC value of 0.013 .mu.g/mL against H. pylori TN2. In addn., this compd. was found to show 60% clearance of H. pylori from infected Mongolian gerbils upon repetitive oral administration (10 mg/kg, b. i. d. for 7 days).

IT 282549-81-9P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);

BIOL (Biological study); PREP (Preparation)

(synthesis and anti-Helicobacter pylori activity of pyloricidin derivs.)

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:475680 HCAPLUS

DOCUMENT NUMBER: 133:105346

TITLE: Preparation of polyol-amino acid compounds having activity against Helicobacter pylori

INVENTOR(S): Kamiyama, Keiji; Nishikimi, Yuji; Hasuoka, Atsushi;

Nakao, Masafumi; Miyagawa, Ken-ichiro; Akiyama, Yohko

PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2000040599 A1 20000713 WO 2000-JP23 20000106  
 W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM,  
 EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR,  
 LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK,  
 SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG,  
 KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,  
 DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 JP 2000256395 A2 20000919 JP 2000-5735 20000106  
 EP 1140979 A1 20011010 EP 2000-900126 20000106  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.:


JP 1999-1898 A 19990107

WO 2000-JP23 W 20000106

OTHER SOURCE(S):

MARPAT 133:105346

GI



AB Title compds. I (X = L-serine, L-asparagine, or (S)-2-aminobutyric acid residue; Y is .alpha.-L-amino acid residue) or their salts or prodrugs having activity against Helicobacter bacteria were prepd. Thus, (S)-3-[[[(2S,3R,4R,5S)-5-[(L-norvalyl-(S)-2-aminobutyl)amino]-2,3,4,6-tetrahydroxyhexanoyl]amino]-3-phenylpropionic acid, prepd. from a leucine-polyol isolated from Bacillus sp. HC-72, showed min. inhibitory concn. 0.025 mg/mL against Helicobacter pylori. Pharmaceutical formulations the above product are given.

IT 282549-81-9P

RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (prepn. of polyol-amino acid compds. having activity against Helicobacter pylori)

REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his 119-123

(FILE 'REGISTRY' ENTERED AT 17:54:08 ON 28 APR 2003)

L19 15 S C24H38N4O9/MF *mol. from.*

L20 8 S L19 AND NR=1 *no. of rings = 1*

L21 1 S 282549-81-9/RN *- see displayed compd, next page*

FILE 'HCAPLUS' ENTERED AT 18:01:44 ON 28 APR 2003

L22 2 S L21 *2 citi from CA Plus - attached*

FILE 'CAOLD' ENTERED AT 18:02:24 ON 28 APR 2003


L23 0 S L22 *0 citi from CA Old*

~~FILE 'HCAPLUS' ENTERED AT 18:02:44 ON 28 APR 2003~~

=&gt; d 121

L21 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2003 ACS  
RN 282549-81-9 REGISTRY  
CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)  
FS STEREOSEARCH  
MF C24 H38 N4 O9  
SR CA  
LC STN Files: CA, CAPLUS

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

2 REFERENCES IN FILE CA (1957 TO DATE)  
2 REFERENCES IN FILE CAPLUS (1957 TO DATE)


=> d ibib abs hitstr 1-1

L17 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 2000:475680 HCAPLUS  
 DOCUMENT NUMBER: 133:105346  
 TITLE: Preparation of polyol-amino acid compounds having activity against Helicobacter pylori  
 INVENTOR(S): Kamiyama, Keiji; Nishikimi, Yuji; Hasuoka, Atsushi; Nakao, Masafumi; Miyagawa, Ken-ichiro; Akiyama, Yohko  
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan  
 SOURCE: PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000040599	A1	20000713	WO 2000-JP23	20000106
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
JP 2000256395	A2	20000919	JP 2000-5735	20000106
EP 1140979	A1	20011010	EP 2000-900126	20000106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: JP 1999-1898 A 19990107  
 WO 2000-JP23 W 20000106

OTHER SOURCE(S): MARPAT 133:105346  
 GI




AB Title compds. I (X = L-serine, L-asparagine, or (S)-2-aminobutyric acid residue; Y is .alpha.-L-amino acid residue) or their salts or prodrugs having activity against Helicobacter bacteria were prepd. Thus, (S)-3-[[[(2S,3R,4R,5S)-5-[(L-norvalyl-(S)-2-aminobutyryl)amino]-2,3,4,6-tetrahydroxyhexanoyl]amino]-3-phenylpropionic acid, prepd. from a leucine-polyol isolated from Bacillus sp. HC-72, showed min. inhibitory concn. 0.025 mg/mL against Helicobacter pylori. Pharmaceutical formulations the above product are given.

IT 282549-81-9P 282549-83-1P  
 RL: BAC (Biological activity or effector, except adverse); BPN (Biosynthetic preparation); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


RN 282549-81-9 HCAPLUS

Absolute stereochemistry.



CN .beta.-Alanine, L-isoleucyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 282549-69-3P 282549-71-7P 282549-73-9P  
282549-75-1P 282549-77-3P 282549-79-5P  
282549-85-3P 282549-87-5P 282549-89-7P  
282549-91-1P 282549-93-3P 282549-95-5P  
282549-98-8P 282550-00-9P 282550-02-1P  
282550-04-3P 282550-06-5P 282550-09-8P  
282550-21-4P

RN 282549-69-3 HCAPLUS

CN .beta.-Alanine, L-norvalyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-  
, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-71-7 HCAPLUS

CN .beta.-Alanine, L-isoleucyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-73-9 HCAPLUS

CN .beta.-Alanine, L-methionyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-75-1 HCAPLUS

CN .beta.-Alanine, L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-77-3 HCAPLUS

CN .beta.-Alanine, L-isoleucyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-79-5 HCAPLUS

CN .beta.-Alanine, L-methionyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282549-85-3 HCAPLUS

CN .beta.-Alanine, L-methionyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 282549-87-5 HCAPLUS

CN .beta.-Alanine, L-asparaginyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-89-7 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-91-1 HCAPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-93-3 HCAPLUS

CN .beta.-Alanine, L-asparaginyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-95-5 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-98-8 HCAPLUS

CN .beta.-Alanine, L-asparaginyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-00-9 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-02-1 HCAPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-04-3 HCAPLUS

CN .beta.-Alanine, L-lysyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-06-5 HCAPLUS

CN .beta.-Alanine, L-valyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-09-8 HCAPLUS

CN .beta.-Alanine, L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (3S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-21-4 HCAPLUS

CN .beta.-Alanine, S-methyl-L-cysteinyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-29-7P


RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219823-29-7 HCAPLUS

CN .beta.-Alanine, L-valyl-L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219823-30-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219823-30-0 HCAPLUS

CN .beta.-Alanine, L-leucyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 219812-79-0P 219812-94-9P 219812-99-4P

219813-00-0P 282549-80-8P 282549-82-0P


RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of polyol-amino acid compds. having activity against *Helicobacter pylori*)

RN 219812-79-0 HCAPLUS

CN Benzenepropanoic acid, .beta.-[(5-amino-5-deoxy-L-galactonoyl)amino]-, (.beta.S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 219812-94-9 HCAPLUS

CN .beta.-Alanine, N-(5-amino-5-deoxy-L-galactonoyl)-3-phenyl-, diphenylmethyl ester, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 219812-99-4 HCAPLUS


CN .beta.-Alanine, O-(1,1-dimethylethyl)-N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 219813-00-0 HCAPLUS  
 CN .beta.-Alanine, O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282549-80-8 HCAPLUS  
 CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282549-82-0 HCAPLUS  
 CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 53064-79-2 77284-64-1

RL: RCT (Reactant); RACT (Reactant or reagent)  
(prepn. of polyol-amino acid compds. having activity against  
Helicobacter pylori)


RN 53064-79-2 HCAPLUS

CN Propanoic acid, 2,2-dimethyl-, iodomethyl ester (9CI) (CA INDEX NAME)



RN 77284-64-1 HCAPLUS

CN Butanoic acid, 2-[[[(1,1-dimethylethoxy)carbonyl]amino]- (9CI) (CA INDEX NAME)



IT 90315-41-6P 219813-07-7P 282549-68-2P  
282549-70-6P 282549-72-8P 282549-74-0P  
282549-76-2P 282549-78-4P 282549-84-2P  
282549-86-4P 282549-88-6P 282549-90-0P  
282549-92-2P 282549-94-4P 282549-96-6P  
282549-97-7P 282549-99-9P 282550-01-0P  
282550-03-2P 282550-05-4P 282550-07-6P  
282550-08-7P 282550-10-1P 282550-11-2P  
282550-12-3P 282550-13-4P 282550-14-5P  
282550-15-6P 282550-16-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of polyol-amino acid compds. having activity against  
Helicobacter pylori)

RN 90315-41-6 HCAPLUS

CN L-Asparagine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 219813-07-7 HCAPLUS

CN Benzenepropanoic acid, .beta.-[[5-[[[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, monohydrochloride, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 282549-68-2 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-70-6 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-72-8 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-74-0 HCAPLUS

CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-76-2 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-isoleucyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-78-4 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 282549-84-2 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-86-4 HCAPLUS

CN .beta.-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-88-6 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-90-0 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-L-cysteinyl-O-(1,1-dimethylethyl)-L-seryl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-92-2 HCAPLUS

CN .beta.-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-N-(triphenylmethyl)-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-94-4 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-96-6 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-L-cysteinyl-N-(triphenylmethyl)-L-asparaginyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282549-97-7 HCAPLUS

CN .beta.-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-L-asparaginyl-(2S)-2-

aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282549-99-9 HCAPLUS

CN .beta.-Alanine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-01-0 HCAPLUS

CN .beta.-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-S-methyl-L-cysteinyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282550-03-2 HCAPLUS

CN .beta.-Alanine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-  
[(phenylmethoxy)carbonyl]-L-lysyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-  
galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

OBu-t

RN 282550-05-4 HCAPLUS

CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-valyl-(2S)-2-aminobutanoyl-5-  
amino-5-deoxy-L-galactonoyl-3-phenyl-, diphenylmethyl ester, (3S)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 282550-07-6 HCAPLUS

CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-norvalyl-(2S)-2-  
aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (3S)- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 282550-08-7 HCAPLUS


CN .beta.-Alanine, N-[(phenylmethoxy)carbonyl]-L-norvalyl-(2S)-2-aminobutanoyl-5-amino-5-deoxy-L-galactonoyl-3-phenyl-, (2,2-dimethyl-1-oxopropoxy)methyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 282550-10-1 HCAPLUS

CN L-Asparagine, N-[(phenylmethoxy)carbonyl]-L-norvalyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 282550-11-2 HCAPLUS

CN L-Asparagine, N-[(1,1-dimethylethoxy)carbonyl]-L-methionyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 282550-12-3 HCAPLUS

CN Benzenepropanoic acid, .beta.-[[5-[[[(2S)-2-amino-1-oxobutyl]amino]-5-deoxy-L-galactonoyl]amino]-, diphenylmethyl ester, monohydrochloride, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 282550-13-4 HCAPLUS


CN Benzenepropanoic acid, .beta.-[[5-[[[(2S)-2-amino-1,4-dioxo-4-[(triphenylmethyl)amino]butyl]amino]-5-deoxy-L-galactonoyl]amino]-, diphenylmethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282550-14-5 HCAPLUS  
 CN L-Asparagine, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-L-norvalyl-  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 282550-15-6 HCAPLUS  
 CN Butanoic acid, 2-[[[(2S)-1-oxo-2-[[[(phenylmethoxy)carbonyl]amino]pentyl]amino]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 282550-16-7 HCAPLUS  
 CN Benzenepropanoic acid, .beta.-[[5-[[[(2S)-2-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-1,4-dioxo-4-[(triphenylmethyl)amino]butyl]amino]-5-deoxy-L-galactonoyl]amino]-, diphenylmethyl ester, (.beta.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS

92662

Access DB# \_\_\_\_\_

**SEARCH REQUEST FORM**

Scientific and Technical Information Center

Requester's Full Name: Mike Miller Examiner #: 69404 Date: 4/28/03  
 Art Unit: 1654 Phone Number: 308-4230 Serial Number: 09 852,887  
 Mail Box and Bldg/Room Location: CM-1-10A-03 Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.  
 \*\*\*\*\*

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: Polyol compounds, their production & use  
 Inventors (please provide full names): Keiji Kamiyama, Yuji Nishikimi, Atsushi  
Hisaoaka, Masafumi Nakao, Ken-ichiro Miyagawa, Yoko  
Akiyama  
 Earliest Priority Filing Date: 11/7/99

\*For Sequence Searches Only\* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

Please Search enclosed structure.  
 EX. 14 No good refs.


Mary Jane Ruhl  
 Tech. Info. Specialist, STIC  
 TC-1600  
 CM-1, Room 6A-06  
 Phone: 605-1155

**STAFF USE ONLY**


\*\*\*\*\*

	Type of Search	Vendors and cost where applicable
Searcher:	NA Sequence (#) _____	STN _____
Searcher Phone #:	AA Sequence (#) _____	Dialog _____
Searcher Location:	Structure (#) _____	Questel/Orbit _____
Searcher Picked Up: <u>4/29/03</u>	Bibliographic _____	Dr. Link _____
Searcher Completed: <u>4/29/03</u>	Litigation _____	Lexis/Nexis _____
Searcher Prep & Review Time: _____	Fulltext _____	Sequence Systems _____
Searcher Prep Time: _____	Patent Family _____	WWW/Internet _____
Search Time: _____	Other _____	Other (specify) _____


Compound of Example 13




Compound of Example 14




Compound of Example 15




Compound of Example 16



Compound of Example 17



Compound of Example 18



K06T90 2825860